Browsing Tag
ASH 2025
5 posts
Can VGA039 become a once-monthly standard of care for von Willebrand disease?
Star Therapeutics' VGA039 shows strong bleeding reduction across all VWD types in Phase 1/2 trial. Discover how this monthly shot could change the standard of care.
Can BeOne’s sonrotoclax become the new backbone of B-cell cancer treatment?
Find out how BeOne Medicines’ sonrotoclax is redefining lymphoma and leukemia treatment with new ASH 2025 data.
Rigel Pharmaceuticals’ R289 delivers promising phase 1b results in transfusion-dependent MDS
Find out how Rigel Pharmaceuticals, Inc. is advancing R289 for lower-risk myelodysplastic syndrome with promising new phase 1b data—read the latest insights now!
CARsgen showcases early clinical results for CT0596 allogeneic BCMA CAR-T cell therapy in multiple myeloma
CARsgen unveils early CT0596 CAR-T trial results at ASH 2025, showing deep responses and strong tolerability in multiple myeloma. See what’s next for the therapy.
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.